Riyaz Bashir News Today

Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute...

The Bashir endovascular catheter was designed to maximize thrombus reduction via a pharmacomechanical infusion.

By Raashid Andrabi SRINAGAR: America’s Food and Drug Administration (FDA) has finally approved the Kashmir cardiologist’s life-saving device that helps in managing pulmonary embolism.

The device to treat pulmonary embolism got approval from the Food and Drug Administration.

A device known as the BASHIR™ Endovascular Catheter (THROMBOLEX, Inc.) significantly reduces the size of blood clots lodged in the pulmonary arteries, leading to improvement in heart function in patients with pulmonary embolism, researchers from the Lewis Katz School of Medicine at Temple University announced in a Late-Breaking Innovation session at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston.

A sham-controlled trial in this progressive, often debilitating disease showed patients treated with a radiofrequency device had longer 6-minute walk times and other benefits.

Trial promising for novel technique

Registry supports expanding use of interventional treatment

The device requires RCT testing against other PE therapies and must show an advantage in hard outcomes, Marc Bonaca says.

Should the pump be used in that setting only in studies for now? Some say yes, others urge selective, cautious use in practice. The new data arent conclusive but have support in earlier research.